Business Wire·May 4, 2026, 8:32 AM ET

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience (NASDAQ: NAGE) launched the clinician-directed Niagen Plus telehealth platform to enable eligible U.S. patients to access prescription-only pharmaceutical-grade Niagen from home.
The launch introduces the first-of-its-kind Niagen At-Home Injection Kit, which facilitates subcutaneous administration & eliminates the need for in-person doctor or pharmacy visits.
The program requires an online medical intake & consultation with a licensed provider, after which a licensed 503A pharmacy dispenses & ships the kit directly to the patient.
The injection kit contains a sterile 500 mg vial of Niagen powder, bacteriostatic water, syringes, needles, alcohol prep pads, & step-by-step instructions via QR code.
The compounded kit is manufactured under cGMP standards & follows clinician-directed dosing protocols of 50 mg or 100 mg.
Clinical safety trials reported the kit was generally safe & well-tolerated at 50 mg/mL & 100 mg/mL dosages with no significant adverse effects.
Injectable administration bypasses gut metabolism, offering a direct delivery pathway with preclinical data suggesting greater tissue availability.
The U.S. injectable industry was valued at USD 223.6 billion in 2025, with the longevity market projected to grow from USD 9.16 billion to USD 20.17 billion between 2025 & 2035.
Niagen Bioscience maintains that the telehealth model ensures quality, clinical oversight, & scientific rigor unlike casual direct-to-consumer purchases.